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Historical conceptualizations of depression
here is a long tradition in phenomenological
psychopathology that stresses basic bodily alterations as
core features of depressive states.Thus,Wernicke used
the term “vital feelings” to describe certain somatic
symptoms occurring in affective psychoses.
1Vital feelings
refer to the close relationship of the body to the aware-
ness of self.They determine the way we experience our
body and the impression we assume our physical pres-
ence makes on other people.Vital feelings are somatic
affects localized in different parts of the body.Whereas
vital feelings constitute the bodily background of our
normal experiences, they may move to the fore in a
depressive mood.For example,depressed patients very
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exactly as an ordinary pain,but more as an unbearable
pressure “like a band around the head.”Other disturbed
vital feelings affect the chest or the abdomen,and medi-
ate unpleasant sensations of weight,tension,heaviness,
or inhibition,totally absorbing the focus of attention.In
quite a similar way Dupré speaks of “coenestopathic
states”which mean a distressing,qualitative change of
normal physical feeling in certain areas of the body dur-
ing an episode of depressive mood.It is a global loss of
vitality in which all bodily parts and functions may be
altered, and all their performances depressed.
2 Kurt
Schneider considered these disturbances of vital feelings
to be the core of cyclothymic depression. In his psy-
chopathological assessment they were of paramount
diagnostic significance in depressive illness,more or less
equivalent to the first-rank symptoms in schizophrenia.
3
Huber discriminated between vital disturbances on the
one hand and vegetative symptoms in depression on the
other.
4Vital disturbances refer to the vital feelings just
mentioned.They comprise a loss of general vital tone of
the body,a prevailing fatigue or exhaustibility,and vari-
ous forms of somatic dysesthesia, typically of a static,
more localized character affecting head, chest, heart
region, or abdomen.All-pervasive sensations of anes-
thesia, stiffness, and alienation of the total body may
characterize a somatopsychic depersonalization in
depression which may appear as a Cotard’s syndrome in
its extreme form.If the vital disturbances take on a pecu-
liar form that is difficult to describe in ordinary everyday
words, Huber speaks of a “coenesthetic” depression
which must be typologically differentiated from the
bizarre states of coenesthetic schizophrenia.Vegetative
symptoms are closely associated with these vital distur-
bances and coenesthesias in depression.Disturbances of
sleep, appetite, and digestion are most frequent.
However,there may be many other vegetative symptoms
in depression such as disordered salivation,transpiration
and lacrimation,cardiac arrhythmias and dyspnea,loss
of libido and various sexual dysfunctions,dys- or amen-
orrhea,loss of or increase in body weight,decreased tur-
gor of the skin,loss of hair,decrease in body tempera-
ture,nausea,vomiting,meteorism,dizziness,sweating,or
sensations of coldness.Both vital disturbances,coenes-
thesias and vegetative symptoms,are typically coexistent
with the well-known affective,behavioral,and cognitive
symptoms of depression.With respect to the different
settings of medical care, however, these psychological
symptoms of depression may be masked by a dominant
reporting of somatic symptoms.M.Bleuler addressed the
point in his book Depressions in Primary Care,in 1943:
“It is a common and frequent observation that depressive
patients with single somatic complaints come to the con-
sulting room of the general practitioner,internal special-
ist,and even the surgeon,gynecologist,ophthalmologist,
urologist and other medical specialists,and spontaneously,
they only speak of somatic phenomena while concealing
their state of depressive mood.They report palpitations,
tightness of the chest,loss of appetite,obstipation,pollak-
iuria,amenorrhea and many others.Only when one looks
at their psychic state does one discover that they report
numerous hypochondriac ideas also in other areas,that in
addition they produce depressive ideas of impoverishment
and sin,that beyond that their whole stream of thoughts is
inhibited,that the depression manifests itself not only in
the somatic complaints reported,but in various other bod-
ily expressions.”
5
In spite of this long-standing psychopathological view on
the somatic foundation of depressive mood, at least in
moderate and severe clinical states,it is bewildering that
the official psychiatric classification systems of the
Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV) and the ICD-10 Classification of
Mental and Behavioral Disorders.Clinical Descriptions
and Diagnostic guidelines (ICD-10) only marginally
appreciate somatic symptoms as diagnostic criteria for
depressive disorders while focussing on the psychologi-
cal symptoms of affect and cognition.So,DSM-IV lists
only three criteria of somatic symptoms for major
depressive disorder:sleep disturbance,appetite distur-
bance,and fatigue or loss of energy.And correspondingly,
in ICD-10, disturbances of sleep and appetite, loss of
libido,and amenorrhea are the only somatic symptoms
considered to be of diagnostic significance for major
depression.Beyond this short list of predominantly veg-
etative symptoms, no painful physical symptoms are
mentioned in either the DSM-IV or ICD-10.There seems
to be a major shift in diagnostic practice, however; the
second version of the Diagnostic and Statistical Manual
of Mental Disorders,4th edition,Text Revision (DSM-IV
TR) now includes new criteria referring to “excessive
worry over physical health and complaints of pain (eg,
headaches or joint, abdominal, or other pains).”
6 This
supplement of diagnostic criteria is indicative of an again-
increasing awareness of the importance of somatic symp-
toms in depression.
Clinical research
228What is meant by “somatic” in 
somatic symptoms of depression?
In the literature there are many terms used to describe
somatic symptoms in depression: somatic, somatized,
physical, bodily, somatoform, painful, psychosomatic,
vegetative, medically unexplained, masked, etc.
7 These
diverse terms refer to different theoretical or diagnos-
tic concepts. For states of depressive mood the neutral
term “somatic” is preferred, comprising various bodily
sensations that a depressed individual perceives as
unpleasant or worrisome.These dysesthesias are very
often localized in certain body parts or organs, or may
affect the whole body in its vital condition,as in the case
of fatigue or loss of energy. Several basic physical dys-
functions, such as those of sleep, appetite, or digestion,
are also to be included in the term “somatic.” In addi-
tion, it may be clinically relevant to differentiate
between painful and nonpainful somatic symptoms of
depression. From a diagnostic perspective one has to
keep in mind that somatic symptoms play a significant
role both in primary psychiatric disorders,first and fore-
most depressive and anxiety disorders, and in somato-
form disorders.And in differential diagnosis, somatic
symptoms must be considered as possibly even indica-
tive of underlying somatic diseases.A diagnostic chal-
lenge may be seen in the well-known fact that depres-
sive, anxiety, somatoform disorders, and medical
conditions are frequently coexistent, or interact in the
individual patient.
8-10 Regarding the assessment of
somatic symptoms, Kroenke correctly points out that
diagnosis very often is more approximative than pre-
cise.Presented somatic symptoms may be either clearly
attributed to a distinct medical disorder or be placed
into one of the following heuristic categories: somato-
form disorder, another primary psychiatric disorder
(often depression and/or anxiety), functional somatic
syndrome (eg, irritable bowel syndrome, fibromyalgia,
chronic fatigue syndrome),“symptom-only” diagnosis
(eg,low back pain,idiopathic dizziness) or only partially
explained by a defined medical disorder (eg, many
states of chronic pain).
11
Epidemiological studies may provide an illuminating
survey of the prevalence of somatic symptoms in depres-
sive disorders, especially those encountered in primary
care, and the prognostic value of somatic symptoms
regarding their development in the further course of ill-
ness.
Somatic symptoms of depressive disorders in
inpatient care and primary care
In a clinical study,Hamilton reported that somatic symp-
toms prevailed in a great majority of depressed patients.
12
Somatic symptoms, particularly somatic anxiety and
fatigue, were documented in up to 80% of a sample of
260 women and 239 men suffering from major depres-
sion.These somatic symptoms very frequently had an
underlying psychopathologically relevant hypochondri-
asis,both in women and men.This study confirmed ear-
lier studies showing that depressive disorders with pre-
dominantly somatic presentation were likely to be the
most common form of depression,both in inpatient and
outpatient care.
13,14 Hagnell and Rorsman stressed the
indicative significance of somatic symptoms in depressed
primary care patients regarding their risk of suicide.
15
Epidemiological studies designed to establish prevalence
figures for depressive disorders in primary care during
recent years have uniformly demonstrated that depres-
sive disorders are highly prevalent at this level of med-
ical care.
16-19 For the great majority of depressed patients
seeking professional help in the official health care sys-
tem,general practitioners and internists are the decisive
interface for diagnosis and treatment of depression.
20
Primary-care patients with depression very often present
with somatic complaints.This seems to be more the rule
than the exception worldwide.
21,22Two of the three most
common symptoms reported during a current depressive
episode were somatic (tired/no energy/listless:73%,bro-
ken sleep/decreased sleep: 63%) as shown by the
European Study Society study (DEPRES II).
23 This
study, however, also underlined that 65% of the
depressed primary care patients suffered from a con-
comitant medical condition pointing to some likely diffi-
culties in differential diagnosis.The multicenter interna-
tional study (n =1146) conducted by the World Health
Organization (WHO) confirmed that two thirds of the
patients presented their depressive mood with somatic
symptoms exclusively,and more than half complained of
multiple medically unexplained somatic symptoms.
24 In
another primary care study,Kirmayer et al arrived at a
similar finding of patients presenting their depressive or
anxiety disorders exclusively with somatic symptoms in
an overwhelming majority (73%).The identified somatic
symptoms were the main reason for the initial visit to the
primary care physician.
25 In a US study in 573 patients
with the diagnosis of major depression,two thirds (69%)
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relationship between pain symptoms and depression.
26
The diagnostic situation in primary care frequently man-
ifests itself, however, as somewhat more complicated.
Many patients present only with a single or a few somatic
symptoms which remain medically unexplained and do
not fulfill the affective and cognitive criteria for a discrete
depressive or anxiety disorder at the end of the clinical
interview.Single somatic symptoms are the primary rea-
son for more than 50% of patients visiting a general prac-
titioner or an outpatient clinic.In some 20% to 25%,these
somatic symptoms are recurrent or chronic.Somatic symp-
toms that remain unexplained after a careful medical
assessment generally bear a high risk for psychiatric mor-
bidity,regardless of the type of symptoms.
27-29 Up to two
thirds of these patients develop a depressive disorder in
the medium term,and between 40% to 50% fulfill the cri-
teria for an anxiety disorder.
30-33 In a cross-sectional study
in 1042 primary care patients,Gerber et al investigated the
differential relationship between specific somatic com-
plaints and underlying depressive symptoms. Some
somatic symptoms showed a high positive predictive value
(PPV) for depression: Sleep disturbances (PPV: 61%),
fatigue (PPV:60%),three or more complaints (PPV:56%),
nonspecific musculoskeletal complaints (PPV:43%),back
pain (PPV: 39%), amplified complaints (PPV: 39%),
vaguely stated complaints (PPV:37%).
34
Some somatic symptoms are typically covariant in the
patients’ complaints without having received the noso-
logical status of a discrete medical condition.These clus-
ters of symptoms are instead considered as functional
somatic syndromes and termed according to the diag-
nostic standards of the various medical disciplines, eg,
fibromyalgia, chronic fatigue syndrome, and irritable
bowel syndrome, etc. For some authors in psychiatry
these functional somatic syndromes represent typical
variants of somatoform disorders.There is still a contro-
versial dispute in the medical literature,however,as to
whether to assemble all these functional somatic syn-
dromes within one general category of somatization,
35,36
or to split them up into separate clinical entities.
37 From
an empirical standpoint, it is remarkable that among
these syndromes there is a significant overlap on the level
of symptoms and a strong association with depressive
and anxiety disorders.
38-41
A close relationship between states of depressive mood
and symptoms of pain, especially of chronic pain, has
been impressively established in many empirical stud-
ies.
26,42-44 Depression and painful symptoms commonly
occur together.As both conditions are highly prevalent
in the general population,their frequent co-occurrence
might be due to mere statistical coincidence.
45,46 From an
empirical standpoint,however,the prevalence figures of
coexistence are far beyond statistical expectation.In a
meta-analytical survey, Bair et al demonstrated that
around two thirds of all depressed patients treated in pri-
mary,secondary,and tertiary centers,both in outpatient
and inpatient settings,report distressing painful somatic
symptoms.
26 Conversely, the prevalence rate of major
depression in patients with various pain syndromes is
about 50%. There seem to be higher rates in clinical
states characterized by multiple diffuse pain symptoms
than by more defined types of pain.The risk of major
depression is considered to be dependent on the sever-
ity, frequency, persistence, and number of pain symp-
toms.
47,48 From the perspective of primary care an epi-
demiological study assessing the predictive power of
chronic pain for depressive morbidity showed that the
prevalence rate of at least one chronic painful physical
condition (CPPC) in the general population was 17.1%.
At least one depressive symptom was present in 16.5%
of subjects; 27.6% of these subjects had at least one
CPPC. Major depression was diagnosed in 4% of sub-
jects,and 43.4% of these subjects had at least one CPPC,
which was 4 times more often than in subjects without
depressive disorder.
49This significant interrelationship of
CPPC and depression confirmed the earlier clinical
advice of Katon, suggesting that if all patients with
painful physical conditions were systematically assessed
regarding a possible underlying depression,some 60% of
all states of depression could be detected in primary
care.
50
Generally, one has to keep in mind that, both from a
cross-sectional and a longitudinal perspective,there is a
relevant overlap of depressive,anxiety,and somatoform
disorders,especially chronic painful physical conditions,
among primary care patients presenting with medically
unexplained symptoms.
51-58 It is an important clinical find-
ing that,with an increasing number of medically unex-
plained symptoms,the risk of an underlying depressive
disorder increases in an impressive dose-response rela-
tionship. In a study which included 1000 adults and
another study comprising 500 patients with a chief com-
plaint of somatic symptoms,the presence of any somatic
symptom increased the likelihood of a mood or anxiety
disorder by two- or threefold.Only 2% of patients with
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but 60% of those patients presented nine or more
somatic symptoms.
31,59 Patients with multiple medically
unexplained somatic symptoms also show a greater
amount of associated other psychiatric comorbidity.
60,61
Somatic symptoms in depression and rates of
diagnostic recognition within primary care
The typical form of presenting a depression in primary
care is via somatization.This form of somatic presentation,
however,is considered to be one of the main reasons for
low rates of recognition of depression in this sector of the
medical care system.
20,62 It must be acknowledged that the
alarmingly low figures of diagnosed and consecutively
treated depressive disorders in only 25% to 33% of
affected patients found in epidemiological studies during
the early 1990s have increased up to some 60%.
17,19 From
a perspective of primary care, general practitioners are
consulted by two groups of depressed patients who may
pose a diagnostic challenge.Patients suffering from a med-
ical condition have a frequent depressive comorbidity.
23,63
These associated depressions often remain undetected,as
the diagnostic focus of the primary care physicians is led
by a dominant model of somatic disease.
64 Indeed,certain
somatic symptoms such as sleep disturbances,diffuse bod-
ily pains and aches,fatigue,changes of appetite,etc,may
characterize both the pathophysiological process of a dis-
crete medical condition and a depressive disorder as well.
The differential diagnosis may be difficult.The role and
significance of somatic symptoms for the diagnosis of
depression in medically ill patients have been a contro-
versial issue in the scientific literature.Meanwhile,a clini-
cally reasonable consensus has been arrived at that the
DSM-IV criteria for major depression do not require sig-
nificant modification for patients with medical comor-
bidities.
65-67 Somatic symptoms can positively contribute to
a diagnosis if they are assessed in line with typical con-
comitant affective,behavioral,and cognitive symptoms of
depression.
9 For a primary care physician it is important to
know that at least 20% to 30% of patients with chronic
medical conditions suffer from a coexisting depression.
68
It must be assumed that,even in those patients being diag-
nosed with an acute somatic disease for the first time,
depression coexists in a significant percentage.
69All in all,
patients with medical conditions are to be considered as a
risk group for nonrecognition of concomitant depression.
70
This especially applies to elderly medically ill patients.
71
In the other major group of depressed primary care
patients,the somatic symptoms complained of very often
remain medically unexplained. If one focuses on the
mode of presentation,about 50% of the patients report
somatic symptoms exclusively,and a minor percentage
of some 20% present their depressive disorder with pre-
vailing psychological, ie, affective and cognitive symp-
toms.
7,21,72,73 There is not, however, a categorical split
between a somatic mode of presentation on the one hand
and a psychological mode on the other.Rather,a broad
spectrum of transition must be assumed,and the grading
of somatization has an impact on the probability of
recognition of an underlying depression.
25As a rule,pri-
mary care physicians do not recognize a depression with
an individual patient better when he or she is complain-
ing of many actual medically unexplained somatic symp-
toms (here they rather prefer a diagnostic standpoint of
wait and see), but when the patient returns again and
again to consult because of these symptoms.
74 In addition,
the extent of hypochondriacal worries and health anxi-
eties facilitate, a correct diagnosis of depression.
75,76
Patients with somatic complaints that are not explained
medically in an adequate way,however,do not represent
a uniform group regarding diagnostic categorization.
Besides depressive disorders,which in primary care man-
ifest themselves according to the traditional concept of
an endogenous type only in minority but instead show
many atypical features,
77-79 one must consider various anx-
iety and somatoform disorders in differential diagno-
sis.
60,61,80-82Again as a rule,there exists an impressive over-
lap on the level of symptoms among all these diagnostic
categories.
10
Aspects facilitating somatic symptoms 
in depression
Many factors may contribute to the form and extent to
which a depression is presented in somatic symptoms.
Female gender has been confirmed to be closely associ-
ated with somatization in many studies covering differ-
ential aspects on various theoretical levels.
83 In a gender
differential analysis,Silverstein draws some interesting
conclusions from the epidemiological data of the
National Comorbity Survey.
84,85 By dividing respondents
into those who met overall criteria for major depression
and exhibited fatigue,appetite,and sleep disturbances
(“somatic depression”) and those who met overall crite-
ria without these somatic symptoms (“pure depression”)
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231she demonstrated gender differences only for “somatic
depression” but not for “pure depression.”The higher
prevalence of “somatic depression” in females was
strongly associated with a high frequency of anxiety dis-
orders.Interestingly,this type of “somatic depression”
among female patients already had its onset during early
adolescent years with predominantly bodily pains and
aches.Wenzel et al attributed the higher prevalence of
“somatic depression” in women largely to changes in
appetite.
86
Gender differences can also be found in primary care.
Women consistently reported most typical somatic symp-
toms at least 50% more often than men.Although men-
tal disorders,above all depressive and anxiety disorders,
were found to be correlated with this mode of somatic
presentation,there was also an independent female gen-
der effect on somatic symptom reporting.
87 In a later
study Jackson et al found that among primary care
patients with somatic symptoms,on the whole,women
were younger, more likely to report stress, endorsed
more “other, currently bothersome” symptoms, were
more likely to have a mental disorder, and were less
likely to be satisfied with the care.
88A greater suscepti-
bility of women,both to psychosocial stress and somatic
illness stress,was held responsible for this higher preva-
lence of depressive and anxiety disorders in female
patients.
89A greater vulnerability to depressive and anx-
iety disorders on the one hand,and a strong neurobio-
logical association to defined functional somatic syn-
dromes (eg, fibromyalgia, irritable bowel syndrome,
chronic fatigue syndrome) on the other may further
increase the extent of this gender difference.
40,90
The disposition both to somatization and to depressive
and anxiety disorder may be intermingled in various
ways.Thus,a depressive mood may trigger the immedi-
ate illness behavior to enter the medical care system and
to report somatized problems caused otherwise.
91 The
very high frequency of somatic anxiety symptoms in
patients with major depression may be interpreted by the
idea that anxiety appears to be a major source of bodily
distress and consecutive hypochondriasis,thus fostering
somatization behavior.
12 Indeed, specific effects of
depression, panic, and somatic symptoms on illness
behavior must be considered.
92 Various causal illness
interpretations,a tendency to amplify somatic distress,
and difficulties in identifying and communicating emo-
tional distress,all have an impact on the form and extent
of a somatic mode of presentation.
93-95Again,regarding
the course of illness,depressive and anxiety disorders fol-
lowing somatoform disorders may significantly con-
tribute to the chronification and complication of the lat-
ter.
39,96
From a perspective of etiologically relevant risk factors
it is a well-established epidemiological finding that the
extent and severity of early adverse events, especially
manifold traumatic experiences, are tightly connected
with the mental and somatic state of adults.This general
disposition may be detected in a series of psychiatric dis-
orders,as in conversion and somatization syndromes,
97-103
several chronic pain conditions,
104-106 hypochondriacal atti-
tudes,
107 factitious disorders,
98 and depressive,anxiety,and
substance disorders.
108-110 One can draw a basic conclusion
from many epidemiologically designed longitudinal stud-
ies that the more a person has been exposed to severe
and early trauma,the higher the risk will be that she/he
will suffering from recurrent or chronic depression with
pronounced suicidality,multiple medically unexplained
somatic symptoms,especially chronic physical pain con-
ditions with an onset already during adolescence or
young adulthood,the more her/his psychic and somatic
state as a whole will be negatively affected,and the more
she/he will demonstrate abnormal illness behavior.
61,111
Culture and society are other factors that may have an
important impact on the way a depressive mood is pre-
sented in a predominantly somatic way.
25 Interestingly,
the comprehensive international WHO study on depres-
sion in primary care, conducted in 12 countries on dif-
ferent continents,was not able to identify clear cultural
influences on the somatic mode of presenting a depres-
sion.A somatic presentation was much more common at
centers where patients lacked an ongoing relationship
with a primary care physician than at centers where most
patients had a personal physician.This variable had a
robustly differentiating effect beyond the various cultural
settings.
24
Besides gender, culture, and type of patient-physician
relationship,there may be many other factors influenc-
ing a more somatic mode of presentation,such as differ-
ent ages in life cycle,association with medical conditions,
earning a lower income,and imprisonment.
7,112
Burden of somatic symptoms in depression
Most patients who are psychopharmacologically treated
for depression fail to reach full remission.
113–114A major-
ity of patients may respond to antidepressants (by defin-
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but still suffer from residual symptoms.These residual
symptoms are often somatic in nature. Symptoms of
somatic anxiety and various painful conditions seem be
especially common in states of incomplete remission.
115
Residual symptoms which are not treated must effec-
tively be considered as a negative risk factor with respect
to earlier relapse,and a more severe and chronic future
course of illness.
116-119
The clinical significance of somatic symptoms in depres-
sion may best be illustrated with the relationship
between depression and painful physical conditions.In
general, the worse the painful somatic symptoms, the
more severe and the longer a depressive episode persists.
In their general population-based study, Ohayon and
Schatzberg found that depressed patients with chronic
pain symptoms reported a longer duration of depressive
mood (19.0 months) than those without chronic pain
(13.3 months).In addition,a chronic physical pain con-
dition in persons with at least one key symptom of
depression was associated with an elevated rate of suici-
dal thoughts.
49 Fishbain considered chronic pain as a
major suicide risk factor in depression.
120Von Korff and
Simon demonstrated a significant correlation between
the intensity of pain symptoms and a worse outcome of
depressive disorders.This worse outcome included more
pain-related functional impairments,a worse state of gen-
eral health,higher rates of unemployment,use of more
opiates,more frequent polypharmacy,and more intensive
utilization of medical services due to pain complaints.
121
Although both painful and nonpainful somatic symptoms
improve with antidepressant treatment,it is the intensity
and extent of pain symptoms at baseline that significantly
contribute to a less favorable response to medication,and
to a longer duration of treatment necessary for a satisfy-
ing result,if at all.
122-124
If one asssembles painful and nonpainful somatic symp-
toms of depression into a single dimension of somatiza-
tion, it is this factor that must be correlated with an
impressively increased overall use of health care services,
125-127 to significant treatment nonadherence and a result-
ing higher risk of relapse and more chronic course of ill-
ness.
128Again,a recurrent or chronic depression includes
a higher risk of suicide
129 and an increased morbidity and
mortality due to illness-inherent factors or associated nat-
ural causes.
130-132All in all,it must be concluded that:when
somatic symptoms,above all painful physical conditions,
accompany the already debilitating psychiatric and behav-
ioral symptoms of depression,the economic burden that
ensues for patients and their employers increases consid-
erably,
133-134 the functional status may be hampered sig-
nifiacantly,
135 and the health-related quality of life is low-
ered dramatically.
136
Neurobiological underpinnings of somatic
symptoms in depression
Various psychosocial and biological stressors may trigger
a depression.Neurobiological processes underlying any
depressive illness are manifold;this applies to the differ-
ent somatic symptoms in particular.A strong heritable
disposition, polygenetic in nature, seems to be estab-
lished,but maladaptive neurobiological stress response
systems already acquired by stressful and traumatic expe-
riences during early development may play a major role
in the pathophysiology of depression as well.
137
Dysfunctions in the serotonergic, noradrenergic, and
dopaminergic neurotransmitter systems have been con-
sidered as relevant for quite a long time.Drawing from
the neuroanatomical serotonergic tracts,starting in the
midbrain raphe cell bodies and projecting to the frontal
cortex,basal ganglia,limbic system,and hypothalamus
on the one hand,of noradrenergic pathways originating
in the locus ceruleus of the brain stem and projecting
again to the same regions of the frontal cortex, limbic
areas,and hypothalamus,but also uniquely to other parts
of the frontal cortex and to the cerebellum on the other,
Stahl stressed that deficiencies in the activity of specific
pathways of serotonin and norepinephrine might account
for the differential clinical phenomenology in depression.
This seems to be true both for the typical psychological
and somatic symptoms. Regarding somatic symptoms,
especially vegetative symptoms such as changes in
appetite or weight,lack of pleasure and sexual appetence,
and sleep abnormalities,dysfunctional hypothalamic and
sleep centers may be of paramount importance,all influ-
enced by both serotonin and norepinephrine.
138 Fatigue,
exhaustibility, or loss of energy, common distressing
symptoms during a depressive episode,but also obstinate
residual symptoms,may be mediated by different mal-
functioning neuronal circuits that are regulated by mul-
tiple neurotransmitters.
139 Fatigue can be experienced as
reduction in either mental or more physical vital feeling.
Likely candidates for the neuronal structures that may
mediate physical fatigue refer to brain areas regulating
motor functions,such as striatum or cerebellum,but also
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from the body and thus modulating the perception of
physical tiredness.In addition to serotonin and norepi-
nephrine, dopamine may be involved in this process.
Mental tiredness,on the other hand,may be mediated by
diffuse cortical circuits and be influenced by cholinergic,
histaminergic,noradrenergic,and dopaminergic neuro-
transmitters.The various painful somatic symptoms in
depression may essentially be associated with serotoner-
gic and noradrenergic pathways descending from brain
stem centers to the spinal cord.An imbalance in these
neurotransmitters,normally serving to inhibit the sensory
input from the intestines, musculoskeletal system, and
other body regions,may accentuate pain sensitivity.
26,140
As a matter of course,neither psychological nor somatic
symptoms in depression can be explained by dysfunc-
tional neurotransmitters exclusively.Many other neuro-
biological processes are involved in the pathophysiology
of depression,such as an abnormal HPA axis with a dis-
ordered feedback mechanism of the corticotropin-releas-
ing factor (CRF) -adrenocorticotropic hormone (ACTH)
- cortisol stress response,a reduced secretion of the neu-
ropeptide hypocretin thus contributing to a desynchro-
nization of the sleep-wake cycle,various abnormalities in
the inflammatory system with an increased production
of certain proinflammatory cytokines,a resulting deple-
tion of the serotonin system, sickness behavior and
depressive mood,reduced concentrations of various neu-
rotrophins such as brain-derived neurotropic factor
(BDNF) causing impaired neuroplasticity,cell resistance,
and neurogenesis.
137,141-147
The intricate pathophysiological interplay of neuroen-
docrine stress response,inflammation,and neurotrans-
mitter systems,both centrally and peripherally,may per-
haps best be illustrated by the relationship between
chronic pain conditions and depressive mood states (suc-
cinctly summarized in refs 148-150). In short, chronic
stress evoked by chronic pain leads to a loss of negative
glucocorticoid feedback in the (hypothalamic-pituitary-
adrenocortical (HPA) axis and downregulation of the
glucocorticoid receptors within the brain and the body
periphery. Inflammation and nerve injury stimulate
nociresponsive neurons within the dorsal horn of the
spinal cord,and the relay of the nociceptive information
ascends to the brain stem to be gated within the thala-
mus,prior to its cognitive appraisal within the somatosen-
sory cortex.Monoaminergic neurons in the brain stem
normally descend to the spinal cord to act as a “brake”
on nociceptive transmission.During chronic pain,loss of
serotonergic and noradrenergic tone in response to glu-
cocorticoid-induced monoaminergic depletion may lead
to descending inhibitory impulses to the spinal cord to
effect an enhancement of pain sensation.Loss of gluco-
corticoid inhibition of proinflammatory cytokines leads
to proliferation of peripheral inflammatory events,con-
tributing to pain sensitization.Although acute stress may
be analgesic,implying an inhibitory circuitry between the
limbic and somatosensory cortices,chronic stress evoked
by chronic pain,leads to downregulation of glucocorti-
coid-mediated activity of this inhibitory connection,caus-
ing enhanced pain perception.Similarly,although acute
pain may be mood-enhancing via both sympathetic and
glucocorticoid routes (implying an excitatory reciprocal
link between the somatosensory and limbic cortices),
chronic pain-induced downregulation of glucocorticoid
modulation of this link may lead to depressed mood.
Psychopharmacological implications for the
treatment of somatic symptoms in depression
Numerous trials with antidepressants have demonstrated
that full remission of the psychological,and especially of
the somatic, symptoms in depression can be achieved
only by a minority group of depressed patients within a
usual 6- to 8-week treatment period.
62,151,152These sober-
ing facts are reflected by a higher risk of relapse,a worse
course of illness with many associated psychosocial dis-
abilities,and a hampered health-related quality of life.
Therefore, achieving a state of symptomatic remission
must be a treatment goal of utmost clinical importance.
Targeting both serotonin and norepinephrine in those
neuronal circuits that mediate somatic symptoms is the
most widely employed strategy to reduce painful and
nonpainful somatic symptoms in depression.
90 In com-
parison with selective serotonin reuptake inhibitors,anti-
depressants with a dual action on both the serotonin and
norepinephrine system were significantly superior in alle-
viating these somatic symptoms and achieving full symp-
tomatic remission of depression.This may be a promis-
ing approach,even to treating chronic pain conditions,
eg, fibromyalgia, without prevailing depressive symp-
toms.
153,154 This seems to have been well established in
clinical trials with venlafaxine,
155-159 duloxetine,
160-163 mil-
nacipran,
164 or mirtazapine.
165 In order to improve dis-
tressing symptoms of fatigue,the use of psychostimulants,
modafinil,bupropion,or selective norepinephrine reup-
Clinical research
234take inhibitors such as reboxetine or atomoxetine may
be recommended.
166
As a rule,psychopharmacological efforts to treat severe
states of depression or states of depression with promi-
nent somatic symptoms effectively must be guided by a
perspective of a longer duration than usual. Higher
dosages of a selected antidepressant have to be used very
often.Sometimes shifts within or between pharmacolog-
ical classes of antidepressants or an augmentation with,
eg,lithium or tri-iodthyronine,are necessary to arrive at
the desired aim.From a pragmatic standpoint,clinically
rational algorithms may favorably guide this endeavor.
167
Finally,it must be stressed that a reasonable combination
of pharmacological and psychotherapeutic approaches
can improve the treatment results in many depressed
patients.
168,169 ❏
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Síntomas somáticos en la depresión
Estados clínicos de ánimo depresivo se caracterizan
esencialmente tanto por síntomas somáticos dolo-
rosos como no-dolorosos. Hasta el momento, este
conocimiento psicopatológico bien establecido ha
sido apreciado sólo insuficientemente por los siste-
mas diagnósticos oficiales del Texto Revisado del
Manual Diagnóstico y Estadístico de los Trastornos
Mentales, Cuarta Edición (DSM-IV-TR) y de la
Clasificación Internacional de los Trastornos
Mentales y del Comportamiento, Descripciones
Clínicas y Guías Diagnósticas en su décima versión
(CIE-10). Desde la perspectiva de los servicios de
atención primaria esta necesidad diagnóstica no
satisfecha es lamentable, ya que el principal modo
de presentación es mediante síntomas somáticos.
Sin embargo, esta forma somática de presentación
contribuye significativamente a reducir la frecuen-
cia de reconocimiento en la atención primaria. Se
puede encontrar un desafío diagnóstico en la dife-
renciación entre una depresión con síntomas somá-
ticos predominantes y la ansiedad, los trastornos
somatomorfos y las condiciones médicas. Cuando
los síntomas somáticos, especialmente las condicio-
nes físicas de dolor, acompañan a los ya debilitan-
tes síntomas psiquiátricos y conductuales de la
depresión, el curso de la enfermedad puede ser más
grave, implicando un mayor riesgo de recaída pre-
coz, cronicidad, suicidio o mortalidad debida a otras
causas naturales, aumento considerable de los cos-
tos económicos, deterioro marcado del estado fun-
cional y disminución dramática de la calidad de vida
relacionada con la salud. Las bases neurobiológicas
de los síntomas somáticos en la depresión pueden
servir de guía para aproximaciones terapéuticas
más promisorias.
Symptômes somatiques dans la dépression
Des symptômes somatiques à la fois douloureux et
non douloureux caractérisent fondamentalement
le stade clinique de l’humeur dépressive. Jusqu’à
présent, cette connaissance psychopathologique
manifeste n’a été qu’insuffisamment évaluée par le
système de diagnostic officiel, le DSM IV TR 4e édi-
tion (Diagnostic and Statistical Manual of Mental
Disorders), et l’ICD-10 (Classification of Mental and
Behavioral Disorders. Clinical Descriptions and
Diagnostic guidelines). Du point de vue des services
de soins primaires, l’absence de diagnostic est
déplorable, la principale manifestation de la
dépression étant marquée par des symptômes
somatiques. Cette forme de présentation soma-
tique est très peu diagnostiquée en soins primaires.
Différencier une dépression accompagnée de symp-
tômes somatiques dominants, de l’anxiété, de
troubles somatoformes, et d’une pathologie médi-
cale, devient un défi diagnostique. Quand des
symptômes somatiques, et en particulier des
troubles physiques douloureux, accompagnent les
symptômes comportementaux et psychiatriques
déjà invalidants de la dépression, l’évolution de la
maladie peut être plus sévère, sous-entendant un
plus fort risque de rechute précoce, de chronicité,
de suicide ou de mortalité due à d’autres causes
naturelles. La charge économique augmente consi-
dérablement, le statut fonctionnel peut être lour-
dement entravé, et la qualité de vie liée à la santé
peut être dramatiquement abaissée. Les bases neu-
robiologiques des symptômes somatiques de la
dépression pourraient permettre une approche du
traitement plus prometteuse.Clinical research
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